Drug Profile
Research programme: anti-malaria therapeutics - Synstar Japan
Latest Information Update: 12 Sep 2023
Price :
$50
*
At a glance
- Originator Synstar Japan
- Class Antimalarials; Heterocyclic compounds
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Discontinued Malaria
Most Recent Events
- 12 Sep 2023 Discontinued - Preclinical for Malaria in Japan (unspecified route)
- 28 Aug 2020 No recent reports of development identified for preclinical development in Malaria in Japan
- 25 Jul 2016 Preclinical trials in Malaria in Japan (unspecified route)